Functional Upregulation of alpha4* Nicotinic Acetylcholine Receptors in VTA GABAergic Neurons Increases Sensitivity to Nicotine Reward
Student Authors
Jennifer NgolabAcademic Program
NeuroscienceUMass Chan Affiliations
Gardner LabTapper Lab
Department of Microbiology and Physiological Systems
Gene Therapy Center
Department of Psychiatry
Brudnick Neuropsychiatric Research Institute
Graduate School of Biomedical Sciences
Document Type
Journal ArticlePublication Date
2015-06-03Keywords
Action Potentials; Animals; Bacterial Proteins; Calbindin 2; Calbindins; Conditioning, Operant; Dihydro-beta-Erythroidine; Dose-Response Relationship, Drug; GABAergic Neurons; Glutamate Decarboxylase; Luminescent Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Nicotine; Nicotinic Agonists; Proto-Oncogene Proteins c-fos; Receptors, Nicotinic; *Reward; Tyrosine 3-Monooxygenase; Up-Regulation; Ventral Tegmental AreaGABA
nicotine
nicotinic receptor
reward
Behavioral Neurobiology
Molecular and Cellular Neuroscience
Substance Abuse and Addiction
Metadata
Show full item recordAbstract
Chronic nicotine exposure increases sensitivity to nicotine reward during a withdrawal period, which may facilitate relapse in abstinent smokers, yet the molecular neuroadaptation(s) that contribute to this phenomenon are unknown. Interestingly, chronic nicotine use induces functional upregulation of nicotinic acetylcholine receptors (nAChRs) in the mesocorticolimbic reward pathway potentially linking upregulation to increased drug sensitivity. In the ventral tegmental area (VTA), functional upregulation of nAChRs containing the alpha4 subunit (alpha4* nAChRs) is restricted to GABAergic neurons. To test the hypothesis that increased functional expression of alpha4* nAChRs in these neurons modulates nicotine reward behaviors, we engineered a Cre recombinase-dependent gene expression system to selectively express alpha4 nAChR subunits harboring a "gain-of-function" mutation [a leucine mutated to a serine residue at the 9' position (Leu9'Ser)] in VTA GABAergic neurons of adult mice. In mice expressing Leu9'Ser alpha4 nAChR subunits in VTA GABAergic neurons (Gad2(VTA):Leu9'Ser mice), subreward threshold doses of nicotine were sufficient to selectively activate VTA GABAergic neurons and elicit acute hypolocomotion, with subsequent nicotine exposures eliciting tolerance to this effect, compared to control animals. In the conditioned place preference procedure, nicotine was sufficient to condition a significant place preference in Gad2(VTA):Leu9'Ser mice at low nicotine doses that failed to condition control animals. Together, these data indicate that functional upregulation of alpha4* nAChRs in VTA GABAergic neurons confers increased sensitivity to nicotine reward and points to nAChR subtypes specifically expressed in GABAergic VTA neurons as molecular targets for smoking cessation therapeutics.Source
J Neurosci. 2015 Jun 3;35(22):8570-8. doi: 10.1523/JNEUROSCI.4453-14.2015. Link to article on publisher's site
DOI
10.1523/JNEUROSCI.4453-14.2015Permanent Link to this Item
http://hdl.handle.net/20.500.14038/33453PubMed ID
26041923Related Resources
Rights
Publisher's PDF posted as allowed by publisher's author rights policy at http://www.jneurosci.org/site/misc/ifa_policies.xhtml. Copyright of all material published in The Journal of Neuroscience remains with the authors. The authors grant the Society for Neuroscience an exclusive license to publish their work for the first 6 months. After 6 months the work becomes available to the public to copy, distribute, or display under a Creative Commons Attribution 4.0 International (CC BY 4.0) license.
Distribution License
http://creativecommons.org/licenses/by/4.0/ae974a485f413a2113503eed53cd6c53
10.1523/JNEUROSCI.4453-14.2015
Scopus Count
Except where otherwise noted, this item's license is described as <p>Publisher's PDF posted as allowed by publisher's author rights policy at http://www.jneurosci.org/site/misc/ifa_policies.xhtml. Copyright of all material published in The Journal of Neuroscience remains with the authors. The authors grant the Society for Neuroscience an exclusive license to publish their work for the first 6 months. After 6 months the work becomes available to the public to copy, distribute, or display under a <a href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International (CC BY 4.0) license</a>. </p>
Related items
Showing items related by title, author, creator and subject.
-
The Role of Medial Habenula-Interpeduncular Nucleus Pathway in Anxiety: A DissertationPang, Xueyan (2015-06-22)Recently, the medial habenula-interpeduncular (MHb-IPN) axis has been hypothesized to modulate anxiety although neuronal populations and molecular mechanisms regulating affective behaviors in this circuit are unknown. Here we show that MHb cholinergic neuron activity directly regulates anxiety-like behavior. Optogenetic silencing of MHb cholinergic IPN inputs reduced anxiety-like behavior in mice. MHb cholinergic neurons are unique in that they robustly express neuronal nicotinic acetylcholine receptors (nAChRs), although their role as autoreceptors in these neurons has not been described. nAChRs are ligand-gated cation channels that are activated by the excitatory neurotransmitter, acetylcholine (ACh), as well as nicotine, the addictive component of tobacco smoke. We expressed novel nAChR subunits that render nAChRs hypersensitive to ACh, ACh detectors, selectively in MHb cholinergic neurons of adult mice. Mice expressing these ACh detectors exhibited increased baseline anxiety-like behavior that was alleviated by blocking the mutant receptors. Under stressful conditions, such as during nicotine withdrawal, nAChRs were functionally upregulated in MHb cholinergic neurons mediating an increase in anxiety-like behavior. Together, these data indicate that MHb cholinergic neurons regulate anxiety via signaling through nicotinic autoreceptors and point toward nAChRs in MHb as molecular targets for novel anxiolytic therapeutics.
-
Nicotinic acetylcholine receptor-mediated mechanisms in lung cancerImprogo, Ma. Reina D.; Tapper, Andrew R.; Gardner, Paul D. (2011-10-15)Despite the known adverse health effects associated with tobacco use, over 45 million adults in the United States smoke. Cigarette smoking is the major etiologic factor associated with lung cancer. Cigarettes contain thousands of toxic chemicals, many of which are carcinogenic. Nicotine contributes directly to lung carcinogenesis through the activation of nicotinic acetylcholine receptors (nAChRs). nAChRs are ligand-gated ion channels, expressed in both normal and lung cancer cells, which mediate the proliferative, pro-survival, angiogenic, and metastatic effects of nicotine and its nitrosamine derivatives. The underlying molecular mechanisms involve increases in intracellular calcium levels and activation of cancer signal transduction pathways. In addition, acetylcholine (ACh) acts as an autocrine or paracrine growth factor in lung cancer. Other neurotransmitters and neuropeptides also activate similar growth loops. Recent genetic studies further support a role for nAChRs in the development of lung cancer. Several nAChR antagonists have been shown to inhibit lung cancer growth, suggesting that nAChRs may serve as valuable targets for biomarker-guided lung cancer interventions.
-
A comparison of brain and behavioral effects of varenicline and nicotine in ratsKing, Jean A.; Huang, Wei; Chen, Wei; Heffernan, Meghan E.; Shields, Jessica; Rane, Pallavi; Bircher, Rhiannon; DiFranza, Joseph R. (2011-09-30)We evaluated the effects of the smoking cessation aid varenicline and nicotine on brain activation, locomotor sensitization and cognitive functioning in rats. Blood oxygenation level dependent (BOLD) activation on fMRI was measured in awake adult male Sprague-Dawley rats in response to their first dose of varenicline 0.04 mg/kg administered intravenously and compared to saline controls. Other groups of rats were pretreated with daily injections of either varenicline 0.04 mg/kg or saline administered subcutaneously over 5 days, and then imaged on the sixth day while receiving an intravenous dose. The initial dose of varenicline produced patterns of brain activation similar to those previously seen with nicotine, increasing BOLD activation in the auditory, cingulate, insular, prefrontal, retrosplenial, temporal and visual cortices, as well as the hippocampus, nucleus accumbens, septum, and ventral tegmental area. However, the sixth dose produced significantly less BOLD activation than the initial dose in the hippocampus, insular cortex, prefrontal cortex, and temporal cortex, suggesting tolerance. Repeated doses of varenicline have thus the opposite effect of repeated nicotine dosing at 24h intervals, previously shown to produce sensitization of brain activation under the same experimental conditions. We also assessed the effects of varenicline on locomotor sensitization and performance in the Morris water maze. Compared to saline controls, varenicline treated rats showed no evidence of locomotor activation or sensitization, and showed improved performance times on the water maze only on the first day. This study points to different effects of varenicline and nicotine on neuronal and behavioral indices.